If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Poisoning === In 1982, the US Mint began minting pennies coated in copper but containing primarily zinc. Zinc pennies pose a risk of zinc toxicosis, which can be fatal. One reported case of chronic ingestion of 425 pennies (over 1 kg of zinc) resulted in death due to gastrointestinal bacterial and fungal sepsis. Another patient who ingested 12 grams of zinc showed only lethargy and ataxia (gross lack of coordination of muscle movements). Several other cases have been reported of humans suffering zinc intoxication by the ingestion of zinc coins. Pennies and other small coins are sometimes ingested by dogs, requiring veterinary removal of the foreign objects. The zinc content of some coins can cause zinc toxicity, commonly fatal in dogs through severe hemolytic anemia and liver or kidney damage; vomiting and diarrhea are possible symptoms. Zinc is highly toxic in parrots and poisoning can often be fatal. The consumption of fruit juices stored in galvanized cans has resulted in mass parrot poisonings with zinc.
The interaction between the chlorine substituent of the thiophene moiety and the aromatic ring of Tyr-228, which is located at the bottom of the S1, it is very important due to the fact that it obviates the need for strongly basic groups for high affinity for FXa. This enables rivaroxaban, which is non-basic, to achieve good oral bioavailability and potency.
Noriega married Felicidad Sieiro in the late 1960s, and the couple had three daughters: Lorena; Sandra; and Thays. Sieiro had been a school teacher, and Noriega a member of the National Guard. Her family, of Basque heritage, was reported to have been unhappy with the marriage. Noriega was repeatedly unfaithful to his wife, who at one point expressed a desire for a divorce, though she changed her mind later.
== External links == Sophora flavescens Ait. Ya Ling, Jian; Ying Zhang, Guo; Jie Cui, Zhao; Kai Zhang, Chang (2007). "Supercritical fluid extraction of quinolizidine alkaloids from Sophora flavescens Ait. and purification by high-speed counter-current chromatography" (PDF). Journal of Chromatography A. 1145 (1–2): 123–127. doi:10.1016/j.chroma.2007.01.080. PMID 17289059. Krishna, Panthati Murali; Knv, Rao; S, Sandhya; Banji, David (2012). "A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae". Revista Brasileira de Farmacognosia. 22 (5): 1145–1154. doi:10.1590/S0102-695X2012005000043.
Sources: en.wikipedia.org
==== 1400–1499 ==== Valuation Timetable (Scotland) Amendment (No.2) Order 1993 (S.I. 1993/1400) Nene Valley Light Railway (Transfer) Order 1993 (S.I. 1993/1402) Home-Grown Cereals Authority (Rate of Levy) Order 1993 (S.I. 1993/1405) Offshore Installations (Safety Zones) Order 1993 (S.I. 1993/1406) High Court and County Courts Jurisdiction (Amendment) Order 1993 (S.I. 1993/1407) Foreign Fields (Specification) Order 1993 (S.I. 1993/1408) Aeroplane Noise (Limitation on Operation of Aeroplanes) Regulations 1993 (S.I. 1993/1409) Fire Safety and Safety of Places of Sport Act 1987 (Commencement No. 7) Order 1993 (S.I. 1993/1411) Sports Grounds and Sporting Events (Designation) (Scotland) Amendment Order 1993 (S.I. 1993/1412) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No. 2) Order 1993 (S.I. 1993/1413) Removal, Storage and Disposal of Vehicles (Prescribed Sums and Charges etc.) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1415) Goods Vehicles (Operators' Licences) (Temporary Use in Great Britain) (Amendment) Regulations 1993 (S.I. 1993/1416) Hackney, Haringey and Islington (London Borough Boundaries) Order 1993 (S.I. 1993/1417) Non-Domestic Rating Act 1993 (Commencement No. 1) Order 1993 (S.I. 1993/1418) Suckler Cow Premium Regulations 1993 (S.I. 1993/1441) Feeding Stuffs (Amendment) Regulations 1993 (S.I. 1993/1442) East London Boroughs (London Borough Boundaries) Order 1993 (S.I. 1993/1443) East London Boroughs (London Borough Boundaries) (No. 2) Order 1993 (S.I. 1993/1444) City and London Borough Boundaries Order 1993 (S.I.
Another challenge facing efforts to control transmission is the fact that although long-term care facilities have been heavily indicated as the primary centers for incidence, amplification, and spread of CRE, studies that have controlled for this transmission have still found CRE spreading in other affiliated hospitals, indicating that long-term acute-care facilities are likely not the sole culprit in the spread of CRE and other multidrug-resistant organisms. One method found effective is to screen and isolate incoming patients from other facilities, and renew focus on hand washing. No new drugs for the bacteria are in development and the bacteria's rapid adaptation to new drugs makes investment in their development unprofitable, as the new drug would quickly become useless. Studies have found that CRE incidence and prevalence can be reduced by applying targeted interventions including increased hygiene measures and equipment sterilization, even in populations where the prevalence of infection exceeds 50% of patients. However, additional environmental cleaning to control transmission has not been verified by controlled trials. The involvement of local and national public health authorities will likely be critical to ensure broader and more sustainable implementation of these measures. Prevention is a top priority for reducing person-to-person transmission of CRE. This is especially true because limited treatment options are available to use after carbapenem resistance develops.
{\displaystyle {\begin{aligned}{\frac {\partial f(t,j)}{\partial t}}&=2k_{+}m(t)f(t,j-1)-2k_{+}m(t)f(t,j)\\&+2k_{\rm {off}}f(t,j+1)-2k_{\rm {off}}f(t,j)\\&+k_{-}\sum _{i=j+1}^{\infty }f(t,i)-k_{-}(j-1)f(t,j)\\&+k_{1}m(t)^{n_{1}}\delta _{j,n_{1}}+k_{2}m(t)^{n_{2}}M(t)\delta _{j,n_{2}}\\\\\end{aligned}}}
Sources: en.wikipedia.org
Their erect posture enabled early dinosaurs to breathe easily while moving, which likely permitted stamina and activity levels that surpassed those of "sprawling" reptiles. Erect limbs probably also helped support the evolution of large size by reducing bending stresses on limbs. Some non-dinosaurian archosaurs, including rauisuchians, also had erect limbs but achieved this by a "pillar-erect" configuration of the hip joint, where instead of having a projection from the femur insert on a socket on the hip, the upper pelvic bone was rotated to form an overhanging shelf.
== History == The founding of the Jere Ngoni Kingdom was precipitated by the Mfecane, a period of widespread instability and state formation in Southern Africa, caused by pre-existing trends of political centralisation which were catalysed by the effects of international trade, environmental instability, and European colonial expansion. An early state was the Ndwandwe led by Zwide; after Zwide defeated Dingiswayo's Mthethwa c. 1816, the Mthethwa state disintegrated and some groups were incorporated into Ndwandwe. Zwide next engaged the expanding Zulu led by Shaka, but was defeated in battle c. 1819. Following this defeat, Zwangendaba (one of Ndwandwe's Indunas) led his group on a long-distance migration northwards, and they became known as the Jere Ngoni (separate from the Maseko Ngoni). Zwangendaba initially settled around the Mkomati River (north of Delagoa Bay), but fled north after clashing with other rulers such as Soshangane, Nxaba, and Mzilikazi. Zwangendaba entered onto the Zimbabwean Plateau and raided the Rozvi Empire for several years, before crossing the Zambezi in 1835. He left some troops behind with a relative of his (Nyamazana) who later killed the Rozvi king. In 1840 Zwangendaba's forces massacred many Tonga for allegedly causing him illness, and they captured many Chewa and Tumbuka. The Ngoni later reached the Ufipa Plateau, where in the late 1840s Zwangendaba died.
The enzyme-linked immunosorbent assay (ELISA) (, ) is a commonly used analytical biochemistry assay, first described by Eva Engvall and Peter Perlmann in 1971. The assay is a solid-phase type of enzyme immunoassay (EIA) to detect the presence of a ligand (commonly a protein) in a liquid sample using antibodies directed against the ligand to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries. In the most simple form of an ELISA, antigens from the sample to be tested are attached to a surface. Then, a matching antibody is applied over the surface so it can bind the antigen. This antibody is linked to an enzyme, and then any unbound antibodies are removed. In the final step, a substance containing the enzyme's substrate is added. If there was binding, the subsequent reaction produces a detectable signal, most commonly a color change. Performing an ELISA involves at least one antibody with specificity for a particular antigen. The sample with an unknown amount of antigen is immobilized on solid support (usually a polystyrene microtiter plate) either non-specifically (via adsorption to the surface) or specifically (via capture by another antibody specific to the same antigen, in a "sandwich" ELISA). After the antigen is immobilized, the detection antibody is added, forming a complex with the antigen. The detection antibody can be covalently linked to an enzyme or can itself be detected by a secondary antibody that is linked to an enzyme through bioconjugation.
== Human use == Different parts of the plant are used as traditional remedies for disease and skin afflictions. Juice from the leaves is used to treat warts and snakebite, and the flower is applied to burns. This species has been used as indigenous traditional medicine in Asia for rheumatism, fractures, and other ailments. In Korean folk medicine, this impatiens species is used as a medicine called bongseonhwa dae (봉선화대) for the treatment of constipation and gastritis. Chinese people used the plant to treat those bitten by snakes or who ingested poisonous fish. Juice from the stalk, pulverised dried stalks, and pastes from the flowers were also used to treat a variety of ailments. Vietnamese wash their hair with an extract of the plant to stimulate hair growth. One in vitro study found extracts of this impatiens species, especially of the seed pod, to be active against antibiotic-resistant strains of Helicobacter pylori. It is also an inhibitor of 5α-reductases, enzymes that converts testosterone to dihydrotestosterone (active form of testosterone), thus reducing action of testosterone in our body. In Nepal, the balsam leaves are crushed to dye fingernails on the day of Shrawan Sakranti (Shrawan 1). The day is also observed as Luto Faalne Deen (Go Away-Itch Day). Similarly, in China and Korea, the flowers are crushed and mixed with alum to produce an orange dye that can be used to dye fingernails. Unlike common nail varnish, the dye is semi-permanent, requiring dyed nails to grow off over time in order to remove any traces of color.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.